First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of ...
The Alpestria-1 study enrolled (in France, USA and Spain) 26 patients with Alport syndrome at high risk of a rapid loss of kidney function despite stable multiple SoC drugs, including ...
Black Diamond Therapeutics’ BDTX lead clinical-stage program, silevertinib (formerly BDTX-1535), is a brain penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor ...
March 17, 2009 (Hollywood, Florida) — The management of dermatologic toxicities associated with the use of epidermal growth-factor-receptor (EGFR) inhibitors in cancer patients is in a nascent stage ...
Black Diamond Therapeutics, Inc. is developing a next-generation EGFR inhibitor with promising early data in lung cancer. BDTX-1535 targets EGFR mutations, especially resistance drivers, with key data ...
Black Diamond Therapeutics Inc. (NASDAQ:BDTX) is one of the best biotech penny stocks to buy according to analysts. On ...
TYK Medicines Inc. made a strong debut on the main board of the Hong Kong Stock Exchange (HKSE), raising HK$579 million (US$74.32 million) to commercialize its lead compound, EGFR inhibitor TY-9591, ...
Schematic diagram of the IL-6/JAK/STAT3 signaling pathway activation in mouse liver macrophages. IRs, inhibitory receptors (IRs); ICIs, immune checkpoint inhibitors; IL-6, interleukin-6; ALT, alanine ...
BlossomHill is also advancing BH-30236, a novel macrocyclic CLK inhibitor targeting aberrant RNA splicing, an important driver of disease progression and therapeutic resistance across multiple cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback